Table 2 Summary of exposure to various antiretroviral drugs among people living with HIV in the US in the IMS Pharmetrics Plus Claims database stratified by regimens containing and not containing abacavir from October 1, 2009 through December 31, 2014
Antiretroviral drug | Total exposure | Exposure in antiretroviral regimens containing abacavir | Exposure in antiretroviral regimens not containing abacavir |
|---|---|---|---|
Tenofovir | |||
 Persons with any exposure – n (%) | 55,804 (76.7) | Not calculated | Not calculated |
 Total person-years of exposure | 80,939 | 2528 | 78,410 |
 Cumulative exposure (years) per person – mean | 2.1 | 0.6 | 2.3 |
Lamivudine | |||
 Persons with any exposure – no. (%) | 14,106 (19.4) | Not calculated | Not calculated |
 Total person-years of exposure | 19,886 | 10,736 | 9150 |
 Cumulative exposure (years) per person – mean | 0.5 | 2.2 | 0.3 |
Zidovudine | |||
 Persons with any exposure – n (%) | 6883 | Not calculated | Not calculated |
 Total person-years of exposure | 9665 | 2074 | 7591 |
 Cumulative exposure (years) per person – mean | 0.3 | 0.5 | 0.2 |
Emtricitabine | |||
 Persons with any exposure – n (%) | 53,377 (73.4) | Not calculated | Not calculated |
 Total person-years of exposure | 76,466 | 693 | 75,774 |
 Cumulative exposure (years) per person – mean | 1.9 | 0.2 | 2.2 |
Efavirenz | |||
 Persons with any exposure – n (%) | 29,795 | Not calculated | Not calculated |
 Total person-years of exposure | 45,930 | 2466 | 43,464 |
 Cumulative exposure (years) per person – mean | 1.2 | 0.6 | 1.3 |
Nevirapine | |||
 Persons with any exposure – n (%) | 3879 | Not calculated | Not calculated |
 Total person-years of exposure | 5880 | 1136 | 4744 |
 Cumulative exposure (years) per person – mean | 0.1 | 0.04 | 0.1 |
Rilpivirine | |||
 Persons with any exposure – n (%) | 4345 | Not calculated | Not calculated |
 Total person-years of exposure | 3778 | 103 | 3675 |
 Cumulative exposure (years) per person – mean | 0 (0–0) | 0 (0–0) | 0 (0–0) |
Atazanavir | |||
 Persons with any exposure – n (%) | 10,470 | Not calculated | Not calculated |
 Total person-years of exposure | 13,862 | 3026 | 10,836 |
 Cumulative exposure (years) per person – mean | 0.4 | 0.6 | 0.3 |
Darunavir | |||
 Persons with any exposure – n (%) | 8871 | Not calculated | Not calculated |
 Total person-years of exposure | 10,394 | 1310 | 9084 |
 Cumulative exposure (years) per person – mean | 0.3 | 0.3 | 0.3 |
Lopinavir | |||
 Persons with any exposure – n (%) | 5596 | Not calculated | Not calculated |
 Total person-years of exposure | 7150 | 1230 | 5920 |
 Cumulative exposure (years) per person – mean | 0.2 | 0.3 | 0.2 |
Fosamprenavir | |||
 Persons with any exposure – n (%) | 1964 | Not calculated | Not calculated |
 Total person-years of exposure | 2699 | 698 | 2001 |
 Cumulative exposure (years) per person – mean | 0.1 | 0.2 | 0.1 |
Raltegravir | |||
 Persons with any exposure – n (%) | 10,537 | Not calculated | Not calculated |
 Total person-years of exposure | 13,663 | 1731 | 11,932 |
 Cumulative exposure (years) per person – mean | 0.4 | 0.4 | 0.4 |